Roger E. Kelley, M.D. Professor and Chairman Department of Neurology Tulane University School of Medicine New Orleans, Louisiana
|
|
- Frank Campbell
- 6 years ago
- Views:
Transcription
1 Roger E. Kelley, M.D. Professor and Chairman Department of Neurology Tulane University School of Medicine New Orleans, Louisiana
2 FINANCIAL DISCLOSURE No potential conflict of interest to disclose.
3 OBJECTIVES AT THE CONCLUSION OF THIS ACTIVITY Define MCI and its subtypes State the diagnostic criteria for MCI including various cognitive screening tools available Ability to discuss the current management/treatment for MCI Ability to discuss the prognosis for MCI including the risk of dementia and the associated mortality risks
4 DEFINITION OF DEMENTIA This term represents a progressive cognitive disturbance which has a number of potential etiologies Can be listed as treatable or untreatable, but this is somewhat subject to interpretation For example, there are several potential treatments for Alzheimer s disease, but the value of such treatment is limited
5 MORE COMMON CAUSES OF DEMENTIA Alzheimer s disease is the most common in subjects in their 50 s and beyond; typically seen beyond age 65 and accounts for roughly 80% of all dementia in the elderly Prior to this age group, one can identify a number of alternative causes, depending upon the population at risk, and this can include: post traumatic dementia, HIVrelated dementia, inborn errors of metabolism, post infectious, etc
6 FRONTO TEMPORAL LOBE DEMENTIA (FTLD) A neurodegenerative form of dementia that tends to occur at an earlier age than Alzheimer s disease and is the third most common form of this type of dementia Characterized by personality change, behavioral disturbance, speech disturbance, inattentiveness and can have associated extrapyramidal features
7 FTLD Features Onset often in the 55 to 65 year range and can be younger Males more affected than females Clinical manifestations, reflective of the selective brain involvement, can include: (1) disinhibition (2) apathy (3) poor insight with impaired judgement (4) perseverative behavior (5) loss of social graces
8 FTLD Features (continued) Can include what has been known as Pick s lobar dementia with characteristic Pick s bodies seen pathologically Is associated with mutations of chromosome 17 with overlap between FTLD and parkinsonism as well as overlap between FTLD and amyotrophyic lateral sclerosis No specific treatment presently available
9 FTLD (continued) See more selective involvement of frontal and temporal lobes on brain imaging as opposed to the more generalized atrophy seen with Alzheimer s disease Cerebral PET scan can help in distinguishing the two entities with AD demonstrating bi parietal hypometabolism on 18 FDG scan versus fronto temporal hypometabolism
10 FTLD MRI Brain Scan
11 COMPARISON IMAGING WITH PET AND MRI BRAIN SCAN
12 ASSOCIATION OF DEMENTIA WITH MOVEMENT DISORDERS Parkinson s Disease is associated with dementia in up to 50% of subjects Dementia with Lewy Bodies Progressive Supranuclear Palsy Cortico basal ganglionic degeneration Huntington s disease FTLD in certain cases
13 DEMENTIA WITH LEWY BODIES Reported to be the second most common type of neurodegenerative dementia after AD Characterized by: (1) cognitive impairment (2) visual hallucinations (3) parkinsonism (4) gait instability with falling tendency (5) sensitivity to neuroleptic agents No specific form of treatment presently available
14 DEMONSTRATION OF LEWY BODIES
15 DEMENTIA ASSOCIATED WITH OTHER DISEASE PROCESSES Multiple sclerosis Leukodystrophies HIV disease Creutzfeldt Jakob Disease (a prion disorder) Neurosyphilis Cryptococcal meningitis Post traumatic Post viral encephalitis
16 ASSOCIATION WITH STROKE Often termed Vascular Dementia or Multi Infarct Dementia Related to either specific involvement of cognitive centers with resultant impairment of communication, memory, executive function, etc or cumulative tissue loss, sometimes reported to be 50 cc s or more, which can be either small vessel or large vessel ischemic or hemorrhagic
17 CUMULATIVE SMALL VESSEL ISCHEMIC TISSUE LOSS CAN LEAD TO DEMENTIA
18 ASSOCIATION WITH CANCER Paraneoplastic syndromes can include limbic encephalitis with cognitive impairment Post radiation encephalopathy is well recognized as a sequela of radiation therapy Chemotherapeutic agents can affect cognitive function
19 ASSOCIATION WITH ALCOHOL Alcohol related dementia is well recognized and can be a direct toxic effect on brain cells or multifactorial such as with associated head trauma related to falling episodes Wernicke Korsakoff s syndrome is not always fully reversible despite expected response of Wernicke s encephalopathy to thiamine
20 ASSOCIATION WITH TRAUMA
21 POTENTIALLY REVERSIBLE FORMS OF DEMENTIA Vitamin B12 deficiency Hypothyroidism Neurosyphilis Cryptococcal meningitis Removal of a chronic subdural hematoma or meningioma Normal pressure hydrocephalus Temporal lobe or Absence status epilepticus
22 RECURRENT SEIZURE ACTIVITY CAN MIMIC DEMENTIA
23 OTHER CONSIDERATIONS So called pseudo dementia in patients with severe depression who have difficulty registering information as part of their distraction and lack of focus Multiple sclerosis, over time, can affect cognitive areas and lead to dementia; there can be particularly malignant forms of demylinating disease such as Schilder s
24 MILD COGNITIVE IMPAIRMENT = MCI MCI identifies a symptomatic pre dementia stage of cognitive impairment Alternative designations have included: cognitive impairment not demented (CIND) and MCI due to Alzheimer s disease which identifies Alzheimer s disease changes as the underlying pathology Not all subjects progress to actual dementia
25 CRITERIA FOR MCI Cognitive complaint, decline or impairment Objective evidence of impairment in cognitive domains Essentially normal functional activities Not demented
26 POTENTIAL COGNITIVE SCREENING TOOLS FOR MCI The Mini Mental Status Exam (MMSE) is probably the most common screening tool for both MCI and dementia. The results are subject to interpretation with 30 as a perfect score and 24/30 or less compatible with dementia of a clinically significant degree However, missing 3/3 objects to remember over 3 to 5 minutes is a very important clinical clue and could identify clinically significant cognitive impairment Alternative testing: Minnesota Cognitive Acuity Screen (MCAS), Delayed Word Recall, Clock Drawing, Enhanced Mental Skills Test (EMST) and Mini Cog
27 LIMITATIONS TO SCREENING TESTS The patients must be engaged and cooperative In terms of short term memory with 3/3 object recall, it is important to ensure that the subject registers the information effectively prior to assessment of the ability to recall later Distracted or depressed patients don t tend to test as well and there can be significant variability
28 PRACTICAL ASPECTS OF COGNITIVE ASSESSMENT What the significant other or family tells you Can the patient effectively manage their affairs including finances? Is the patient safe to live alone? Is the patient safe to drive? These aspects sometimes require formal neuropsychological testing instead of a screening test
29 MCI SUBTYPES Amnestic MCI = clinical impairment reflective of memory impairment Non amnestic MCI is characterized by impairment in one or more non memory impairment cognitive domains including executive function/attention, language and visuospatial skills
30 MULTIPLE DOMAIN MCI This denotes a greater extent of disease with impairment found in more than one cognitive domain This will theoretically progress to dementia more readily than single domain MCI The progression of MCI to dementia reflects whether or not there is associated neurodegeneration i.e, atrophy of the hippocampus
31 MCI AS MORE OF A GENERIC TERM There is the potential for non amnestic MCI to progress to non Alzheimer s forms of dementia such as fronto temporal dementia which tends to be characterized by disinhibiton with personality change, with single domain involvement with neurodegeneration, while Dementia with Lewy bodies would be more likely seen with multiple domain involvement
32 MCI MAY REFLECT A REVERSIBLE PROCESS Cognitive impairment can be associated with sedative use, narcotic pain medication use, excessive ingestion of EtOH or use of illicit drugs such as heroin, meth or cocaine MCI can precede vascular dementia which may have a variable course depending upon the degree of involvement and the potential for recovery from an ischemic or hemorrhagic CNS insult
33 PREVALENCE OF MCI For subjects 60 years of age or older, the prevalence estimates range from 16 to 20% There is great variability reflective of comorbid factors including age, sex, level of education, ethnic background, presence of APO E4 allele as well as co morbid factors such as vascular disease, various medication needs as well as potential psychiatric factors
34 EVOLUTION OF MCI TO DEMENTIA The figure cited as 20 to 40% over time with 10 to 15% per year However, this is quite variable with vascular risk factors playing a potentially important role in the overlap of neurodegenerative dementia, such as AD, and vascular dementia Biomarkers such as structural brain atrophy, APO E4 status, PET, etc can presumably enhance predictive power
35 POTENTIAL RESOLUTION OF MCI It has been reported that up to 20% of subjects with MCI improve rather than progress over time and some return to normal cognitive status This underscores the potential contribution of EtOH consumption, illicit drug or prescribed drug use, medical condition and emotional status at the time of initial evaluation
36 OVERALL PROGNOSIS OF MCI Related to multiple factors including the age of the subject, co morbid medical factors including medications, level of social support, number of domains affected, emotional state including pre morbid personality MCI in and of itself should not affect life expectancy to a significant degree unless it translates into dangerous behavior
37 POTENTIAL DANGERS WITH MCI Forgetting to turn off the stove or other activities that could wreak havoc Getting lost while driving or impaired driving capacity Forgetting to takes one s medications Forgetting healthy lifestyle measures including keeping doctor visits and seeking medical help for new symptoms Potential impaired sense of smell
38 TREATMENT AND POSSIBLE PREVENTION OF MCI Promotion of a healthy lifestyle in terms of diet, exercise, control of risk factors for vascular disease, good diabetic control, compliance with medications, smoking cessation, avoidance of excess alcohol, abstinence from illicit drugs and avoidance of medications that blunt cognition such as benzodiazepines Avoiding concussions
39 Measures that May Preserve Cognition Active mental and physical exercise program Special diets such as the MIND diet or the Mediterranean diet Vitamin E 2000 IU a day Vitamin D IU a day Recent reports of association with protein pump inhibitors Some reports of potential deleterious effect of statins
40 TREATMENT OF MCI Keep a notebook of what you need to remember Avoid sleep deprivation Cholinesterase inhibitors may provide some benefit The n methyl d aspartate (NMND) receptor blocker memantine may provide some benefit
41 ALZHEIMER S DISEASE REFLECTED BY PROGRESSIVE BRAIN ATROPHY
42 ALZHEIMER S DISEASE COMPARISON
43 Alzheimer s Disease Defined A neurodegenerative disorder characterized by progressive cognitive decline Related to the aging process and typically seen in patients in their 60 s and beyond although occasionally seen in younger patients Increasing recognition that there is a genetic predisposition for a number of patients
44 DIAGNOSIS OF ALZHEIMER S DISEASE A clinical diagnosis in which alternative explanations for the dementing illness are ruled out Based on the history provided, usually by the family or significant other, the lack of an alternative explanation, the clinical course, and routine diagnostic studies
45 DOCUMENTATION OF THE DEMENTIA The mini mental status exam is often used by clinicians with a score of 24/30 or below being compatible with dementia Formal neuropsychological evaluation with a battery of cognitive tests is potentially helpful for more accurately determining the cognitive realms involved and the patient s level of capability in terms of finances, driving capacity, etc.
46 ROUTINE DIAGNOSTIC STUDIES Standard lab tests include a CBC to assess for a significant hematological disorder that might be related to the presentation, an ESR to screen for an inflammatory, infectious or neoplastic process, metabolic studies including renal and liver function as well as potential effect of a low or high serum sodium, calcium, magnesium or phosphorus
47 ADDITIONAL DIAGNOSTIC STUDIES Serum B12 and folate level Thyroid profile Toxicology and possibly heavy metal screen Syphilis serology and HIV testing when appropriate MRI or CT brain scan to evaluate for a mass lesion, e.g. chronic SDH, hydrocephalus, cerebovascular disease
48 CEREBROSPINAL FLUID Can be useful for CSF VDRL, cryptococcal antigen, and to assess for other infectious or inflammatory disorders such as Lyme disease and neurosarcoidosis Measurement of CSF beta amyloid protein (decreased) and tau protein (increased) can be quite sensitive for the detection of Alzheimer s disease of the order of 95%
49 EEG Can be useful for patients with episodic confusion which could reflect an epileptic disturbance Can also be of value in the more rapid developing dementia seen with Creutzfeldt Jakob disease
50 EEG in Patient with Epilepsy
51 CJD EEG: Pseudo Periodic Triphasic and Biphasic Discharges
52 Brain Imaging in Dementia This is standard to rule out alternative explanations to AD Evaluate for possible cerebrovascular component, with MRI superior to CT brain scan for small vessel ischemic disease, hydrocephalus, late onset leukodystrophy or structural lesion such as a subdural hematoma or neoplasm
53 DIFFUSE ATROPHY ON CORONAL MRI IN AD
54 VOLUMETRIC ANALYSIS OF HIPPOCAMPAL ATROPHY IN AD
55 POSITRON EMISSION TOMOGRAPHY (PET) IMAGING Cerebral PET scan with either 18 FDG, Pittsburgh Compound B (PIB), a ligand that attaches to brain β amyloid plaques vs 18 F labeled amyloid PET tracers such as commercially available 18 F florbetapir Tau labeled tracers are now also available for detection of alternative pathology of Alzheimer s disease
56 18 FDG PET in Alzheimer s Disease: Normal vs AD
57 Pittsburgh Compound B PET
58 Florbetapir Amyloid PET scan in AD: A negative (gray contrast less intense) and B is positive
59 Beta Amyloid PET scan
60 TAU CEREBRAL PET SCAN IN NORMAL VS EARLY AD
61 APOLIPOPROTEIN E4 ALLELE TESTING Can provide some prognostic and potentially diagnostic information Normal subjects heterozygous for the APO E4 allele have a roughly 2 fold increased risk of developing AD while subjects who are homozygous have a 12 fold increased risk Heterozygous subjects with dementia have a roughly 85% chance of AD as an explanation and this with 95% for those homozygous
62 Role of APO E4 in the Pathogenesis of Alzheimer s APO E4 is the major known genetic risk factor for AD APO E4 carriers account for 65 to 80% of all AD cases Transgenic mouse models which express different apoe isoforms demonstrate potential neurotoxic contribution via apoe4 fragments as well as effect on beta amyloid and tau protein deposition in neurons and astrocytes
63 DEFINITIVE DIAGNOSTIC CRITERION FOR AD The diagnosis is only definitive when there are typical neuropathological findings of AD including: (1) beta amyloid plaques (2) neurofibrillary tangles (3) granulovacuolar degeneration (4) neuronal and synapse loss Lewy bodies are not uncommon in AD as well Clinical diagnostic accuracy now approaches 90%
64 Beta amyloid (Senile) Plaques
65 NEUROFIBRILLARY TANGLES FROM HYPERPHOSPHORYLATED TAU PROTEIN
66 ALZHEIMER S PATHOLOGY: AMYLOID PLAQUE AND NEUROFIBRILLARY TANGLE
67 LEWY BODY WHICH CAN BE SEEN IN AD AS WELL
68 Alzheimer s Disease Clinical Course Evolves over time and can be preceded by mild cognitive impairment (MCI) which can help identify those at risk for developing AD It is not unexpected to lose some memory function as part of the luxury of growing older as opposed to the alternative Just as our eyes, skin, bones, GI tract, etc age, so do our brains
69 Clinical Issues of Note AD manifestation is reflective of several factors such as baseline IQ, educational level, socio economic level and level of family support and protection Becomes clinically relevant when it begins to impact on functional independence and the quality of life
70 Compensatory Mechanisms Patients with AD are familiar, and comfortable, with their typical surroundings and can decompensate when taken out of a familiar setting; this can lead to serious consequences such as when an Alzheimer s patient needs to be hospitalized for another condition There is the potential for relatively minor issues to cause decompensation, e.g. a UTI
71 Concept of Break Point Patients with AD can chug along with various mechanisms to correct for their deficiencies such as writing things down, being overly defensive, becoming more socially withdrawn to avoid social challenges However, there can be an eventual point where they are no longer able to effectively compensate and the family has to step in and this can occur rather suddenly
72 Major Challenges for the Patient and Family Loss of driving privileges when it is no longer felt to be safe for the person with any form of dementia to be driving Financial issues as, believe it or not, people might take advantage of the cognitive impairment for their own benefit Safety issues in terms of associated loss of sense of smell; spoiled food may not be detected and cannot smell smoke
73 Manifestations Typically see progressive short term greater than longer term memory loss Progressive loss of ability to carry out task i.e. loss of executive function Can see loss of initiative, social withdrawal with personality change Can be selective in terms of aphasia (affecting dominant hemisphere) versus right hemispheric visuo spatial difficulty
74 Aggressive Behavior and Loss of Impulse Control This can be both embarrassing, for a former pillar of the community, as well as potentially dangerous Can strike out physically at their loved ones, wander off, engage in activity reflective of loss of appropriate judgment in terms of affairs, financial schemes, etc Cortex no longer as inhibitory as it once was
75 MANAGEMENT ISSUES Avoiding stressors Avoiding medications that can promote confusion such as benzodiazepines and certain sleeping aides; melatonin is a good first choice as a sleeping aide The so called enriched environment in which manageable mental challenges are promoted such as reading, mind games, etc
76 MEDICATIONS Cholinesterase inhibitors which include Aricept (now released at a 23 mg per day dose) versus the 10 mg a day dose, Razadyne and Exelon (available both orally and as a patch) Memantine (Namenda) which is an N methyl D aspartate receptor blocker Axona which is a food supplement designed to improve cerebral metabolism
77 Prognosis in Alzheimer s Disease Typically see progression to an advanced dependent stage over 5 years with some evidence that cholinesterase inhibitors promote some degree of delay of the progression as well as some potential benefit with memantine Most patients live for 8 to 10 years with women tending to survive longer than men
78 Prognosis II. Roughly 25% of women live for longer than 8 years from the time of diagnosis Some subjects live for up to 20 years Now the 8 th leading cause of death in the United States and the most common contributing factor is infection
79 Prognosis III. Factors which impact negatively on prognosis include: (1) age (2) co morbid conditions such as CHF (3) male sex (4) gait instability (5) wandering (5) incontinence (5) bedridden condition (6) pressure sores (7) dyspnea Roughly 50% of patients with advanced dementia who suffer either a hip fracture or pneumonia will be dead within the year
80 SUMMARY The prevalence of AD in the United States is presently 4 to 4.5 million There will be an increasing epidemic as the baby boomers reach age 65 and older Therapy remains limited and recent clinical trials of monoclonal antibodies against beta amyloid plaques as well as secretase enzyme inhibitors have been negative
WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More informationAssessing and Managing the Patient with Cognitive Decline
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
More informationDiagnosis and Treatment of Alzhiemer s Disease
Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised
More informationDelirium & Dementia. Nicholas J. Silvestri, MD
Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts
More informationNon Alzheimer Dementias
Non Alzheimer Dementias Randolph B Schiffer Department of Neuropsychiatry and Behavioral Science Texas Tech University Health Sciences Center 9/11/2007 Statement of Financial Disclosure Randolph B Schiffer,,
More informationALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey
ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationMemory Loss, Dementia and Alzheimer's Disease: The Basics
Memory Loss, Dementia and Alzheimer's Disease: The Basics What is memory loss? What is age-related memory loss? Typical changes Typical age-related changes involve: Making a bad decision once in a while
More informationDiagnosis and management of non-alzheimer dementias. Melissa Yu, M.D. Department of Neurology
Diagnosis and management of non-alzheimer dementias Melissa Yu, M.D. Department of Neurology AGENDA Introduction When to think of alternate diagnoses Other forms of dementia Other reasons for confusion
More informationDEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
More informationDementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology
Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language
More informationDementia. Assessing Brain Damage. Mental Status Examination
Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological
More informationDEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD
DEMENTIA 101: WHAT IS HAPPENING IN THE BRAIN? Philip L. Rambo, PhD OBJECTIVES Terminology/Dementia Basics Most Common Types Defining features Neuro-anatomical/pathological underpinnings Neuro-cognitive
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More informationCaring Sheet #11: Alzheimer s Disease:
CARING SHEETS: Caring Sheet #11: Alzheimer s Disease: A Summary of Information and Intervention Suggestions with an Emphasis on Cognition By Shelly E. Weaverdyck, PhD Introduction This caring sheet focuses
More informationAlzheimer s disease dementia: a neuropsychological approach
Alzheimer s disease dementia: a neuropsychological approach Dr. Roberta Biundo, PhD Neuropsychology Coordinator at Parkinson s disease and movement disorders unit of San Camillo rehabilitation hospital
More informationDifferentiating Dementia Diagnoses
Differentiating Dementia Diagnoses Waitemata PHO 21 October 2014 Dr Michal Boyd, RN, NP, ND Nurse Practitioner Older Adults School of Nursing & Freemasons Dept. of Geriatric Medicine The University of
More informationAlzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia.
CHAPTER 3 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease
More informationComments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues
Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical
More informationClinical Diagnosis. Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV)
Step 1: Dementia or not? Diagnostic criteria for dementia (DSM-IV) A. The development of multiple cognitive deficits manifested by both 1 and 2 1 1. Memory impairment 2. One (or more) of the following
More informationYin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre
Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5
More informationFact Sheet Alzheimer s disease
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
More informationDementia and Delirium: A Neurologist s Approach to Altered Mental Status. Case 1 4/7/11. Which of the following evaluations is your next step?
Dementia and Delirium: A Neurologist s Approach to Altered Mental Status S. Andrew Josephson, MD Director, Neurohospitalist Program Medical Director, Inpatient Neurology University of California San Francisco
More informationWhat APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias
What APS Workers Need to Know about Frontotemporal, Lewy Body and Vascular Dementias Presenter: Kim Bailey, MS Gerontology, Program & Education Specialist, Alzheimer s Orange County 1 1 Facts About Our
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationDementia and Alzheimer s disease
Since 1960 Medicine Korat โรงพยาบาลมหาราชนครราชส มา Dementia and Alzheimer s disease Concise Reviews PAWUT MEKAWICHAI MD DEPARTMENT of MEDICINE MAHARAT NAKHON RATCHASIMA HOSPITAL 1 Prevalence Increase
More informationOLD AGE PSYCHIATRY. Dementia definition TYPES OF DEMENTIA. Other causes. Psychiatric disorders of the elderly. Dementia.
Psychiatric disorders of the elderly OLD AGE PSYCHIATRY Dementia Depression Delusional disorder/late onset schizophrenia Delirium Dementia definition LOCALISATION OF CEREBRAL FUNCTION Impairment of multiple
More informationA Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies
A Fresh View of Cognitive Disorders in Older Adults: New Classification and Screening Strategies Lynda Mackin, PhD, AGPCNP-BC, CNS University of California San Francisco School of Nursing 1 Alzheimer s
More information4/11/2017. The impact of Alzheimer s disease. Typical changes. The impact of Alzheimer s disease. Problematic changes. Problematic changes
The impact of Alzheimer s disease Ron Petersen, MD, PhD, is Director of the Mayo Alzheimer's Disease Research Center. 2 The impact of Alzheimer s disease Typical changes Typical age-related changes involve:
More informationMild Cognitive Impairment
Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s
More informationALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health
ALZHEIMER S DISEASE OVERVIEW Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health Prevalence AD: DEMOGRAPHY AND CLINICAL FEATURES Risk and protective factors Clinical features and
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationWhat is dementia? What is dementia?
What is dementia? What is dementia? What is dementia? Dementia is an umbrella term for a range of progressive conditions that affect the brain. It has been identified that there are over 200 subtypes of
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationDementia Basics. Welcome! What to expect and how to handle a dementia diagnosis. In partnership with Scripps Health.
Dementia Basics What to expect and how to handle a dementia diagnosis March 18, 2017 In partnership with Scripps Health Welcome! 1 Welcome Kristin Gaspar San Diego County Supervisor District 3 2 Our Mission:
More informationFRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
More informationA BRIEF LOOK AT DEMENTIA
Dementia A BRIEF LOOK AT DEMENTIA David Kaufman, MD Neurology Consultants of Bellin Health November 2, 2017 Defined as a progressive decline in cognitive function that impairs daily activities. Always
More informationP20.2. Characteristics of different types of dementia and challenges for the clinician
P20.2. Characteristics of different types of dementia and challenges for the clinician, professor Danish Dementia Research Center Rigshospitalet, University of Copenhagen (Denmark) This project has received
More informationIntroduction to Dementia: Diagnosis & Evaluation. Created in March 2005 Duration: about 15 minutes
Introduction to Dementia: Diagnosis & Evaluation Created in March 2005 Duration: about 15 minutes Axel Juan, MD The Geriatrics Institute axel.juan@med.va.gov 305-575-3388 Credits Principal medical contributor:
More informationForm A3: Subject Family History
Initial Visit Packet NACC Uniform Data Set (UDS) Form A: Subject Family History ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by a clinician
More informationEpilepsy in dementia. Case 1. Dr. Yotin Chinvarun M..D. Ph.D. 5/25/16. CEP, PMK hospital
Epilepsy in dementia Dr. Yotin Chinvarun M..D. Ph.D. CEP, PMK hospital Case 1 M 90 years old Had a history of tonic of both limbs (Lt > Rt) at the age of 88 years old, eye rolled up, no grunting, lasting
More informationDementia is not normal aging!
The Future of Alzheimer s Disease Treatment Adam L. Boxer, MD, PhD Director, Alzheimer s Disease Clinical Trials Program Memory and Aging Center Assistant Professor of Neurology University of California,
More informationResearch ALZHEIMER S DISEASE AND RISK FACTORS
Research ALZHEIMER S DISEASE AND RISK FACTORS What is Alzheimer s disease? Alzheimer s disease is the most common of a large group of disorders known as dementias. It is an irreversible disease of the
More informationWEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES
WEBINAR SERIES: AGING IN INDIVIDUALS WITH INTELLECTUAL AND DEVELOPMENTAL DISABILITIES 1 CMS Medicare-Medicaid Coordination Office (MMCO) Established by Section 2602 of the Affordable Care Act Purpose:
More informationCognitive disorders. Dr S. Mashaphu Department of Psychiatry
Cognitive disorders Dr S. Mashaphu Department of Psychiatry Delirium Syndrome characterised by: Disturbance of consciousness Impaired attention Change in cognition Develops over hours-days Fluctuates during
More informationAlzheimer s Disease without Dementia
Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and
More informationOld Age and Stress. Disorders of Aging and Cognition. Disorders of Aging and Cognition. Chapter 18
Disorders of Aging and Cognition Chapter 18 Slides & Handouts by Karen Clay Rhines, Ph.D. Northampton Community College Comer, Abnormal Psychology, 8e Disorders of Aging and Cognition Dementia deterioration
More informationThe Person: Dementia Basics
The Person: Dementia Basics Objectives 1. Discuss how expected age related changes in the brain might affect an individual's cognition and functioning 2. Discuss how changes in the brain due to Alzheimer
More informationEvaluation and Treatment of Dementia
Evaluation and Treatment of Dementia Jeffrey M. Burns, MD Edward H. Hashinger Professor of Neurology Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science Unit Disclosures
More information7/3/2013 ABNORMAL PSYCHOLOGY SEVENTH EDITION CHAPTER FOURTEEN CHAPTER OUTLINE. Dementia, Delirium, and Amnestic Disorders. Oltmanns and Emery
ABNORMAL PSYCHOLOGY SEVENTH EDITION Oltmanns and Emery PowerPoint Presentations Prepared by: Ashlea R. Smith, Ph.D. This multimedia and its contents are protected under copyright law. The following are
More informationWhat is dementia? What is dementia?
What is dementia? What is dementia? What is dementia? Dementia is an umbrella term for a range of progressive conditions that affect the brain. There are over 200 subtypes of dementia, but the five most
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationAlzheimer s Disease. Pathophysiology: Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior,
2 Alzheimer s Disease Alzheimer s disease (AD) is a progressive dementia affecting cognition, behavior, and functional status with no known cause or cure. Patients eventually lose cognitive, analytical,
More informationNew life Collage of nursing Karachi
New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology
More informationDementia. Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine
Dementia Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine What is Dementia? Dementia is a general term referring to a decline in cognitive/mental functioning; this decline
More informationDementia. Understanding 9/20/2010. Jan Robson Coordinator of the Alzheimer Society's Dementia Helpline
Understanding Dementia Jan Robson Coordinator of the Alzheimer Society's Dementia Helpline Marc Labrecque Provincial Coordinator of Programs and Services 1 Understanding Dementia What is dementia Alzheimer
More informationDementia Update. Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota
Dementia Update Daniel Drubach, M.D. Division of Behavioral Neurology Department of Neurology Mayo Clinic Rochester, Minnesota Nothing to disclose Dementia Progressive deterioration in mental function
More informationWhat s Causing Your Memory Loss?
What s Causing Your Memory Loss? It s Not Necessarily Alzheimer s More than 50 conditions can cause or mimic the symptoms of dementia, and a small percentage of dementias are reversible. Two common examples
More informationIs it Alzheimer s or Another Dementia? Reversible dementias. Key Points. Delirium. Toxic reactions to drugs
Is it Alzheimer s or Another Dementia? Bonus Article for HELPGUIDE.ORG from Harvard Health Publications For physicians and families intent on pinning down a diagnosis, one major complicating factor is
More informationWhat is dementia? alzheimers.org.uk
alzheimers.org.uk What is dementia? If you, or a friend or relative, have been diagnosed with dementia, you may be feeling anxious or confused. You may not know what dementia is. This factsheet should
More informationCognitive Screening in Risk Assessment. Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University.
Cognitive Screening in Risk Assessment Geoffrey Tremont, Ph.D. Rhode Island Hospital & Alpert Medical School of Brown University Outline of Talk Definition of Dementia and MCI Incidence and Prevalence
More informationUnderstanding Symptoms, Causes, and Risks for Alzheimer s Disease
Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging
More informationFTD basics! Etienne de Villers-Sidani, MD!
FTD basics! Etienne de Villers-Sidani, MD! Frontotemporal lobar degeneration (FTLD) comprises 3 clinical syndromes! Frontotemporal dementia (behavioral variant FTD)! Semantic dementia (temporal variant
More informationDementia and Delirium:
Dementia and Delirium: A Neurologist s Approach to Altered Mental Status S. Andrew Josephson MD Carmen Castro Franceschi and Gladyne K. Mitchell Neurohospitalist Distinguished Professor Senior Executive
More informationDr Georgina Train Consultant Psychiatrist EMDASS service and Continuing Care.
Dr Georgina Train Consultant Psychiatrist EMDASS service and Continuing Care. Consultant Psychiatrist of both General adult and Old Age Psychiatry. Work with Memory Service and a Continuing Care ward.
More informationDEMENTIA. Szabolcs Szatmári. Tg. Mureş Marosvásárhely Romania 4/18/ :59 AM
DEMENTIA Szabolcs Szatmári Tg. Mureş Marosvásárhely Romania Dementia from Latin de- "apart, away" + mens (genitive mentis) "mind" MORE GRAY HAIR AND LESS GRAY MATTER Daryl R. Gress Cognitive decline
More informationBrain Health and Risk Factors for Dementia
Welcome To Brain Health and Risk Factors for Dementia Presented by Kamal Masaki, MD Professor and Chair Department of Geriatric Medicine John A. Burns School of Medicine, UH Manoa April 4, 2018 10:00 11:00
More informationEvaluations. Alzheimer s Disease A Public Health Response. Viewer Call-In. July 19, Guest Speakers. Thanks to our Sponsors:
Alzheimer s Disease A Public Health Response July 19, 2007 1 2 Guest Speakers Thanks to our Sponsors: Earl A. Zimmerman, M.D. Bender Endowed Chair of Neurology and Director of the Alzheimer s Center at
More informationIs PET/CT really helpful in diagnosing Alzheimer s Disease?
Is PET/CT really helpful in diagnosing Alzheimer s Disease? J. Rudolf MD Ph.D. Consultant in Neurology, Dept. of Neurology, General Hospital Papageorgiou Thessaloniki, Greece Conflict of Interest PET/CT
More informationClinicopathologic and genetic aspects of hippocampal sclerosis. Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA
Clinicopathologic and genetic aspects of hippocampal sclerosis Dennis W. Dickson, MD Mayo Clinic, Jacksonville, Florida USA The hippocampus in health & disease A major structure of the medial temporal
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationDementia. Aetiology, pathophysiology and the role of neuropsychological testing. Dr Sheng Ling Low Geriatrician
Dementia Aetiology, pathophysiology and the role of neuropsychological testing Dr Sheng Ling Low Geriatrician Topics to cover Why is dementia important What is dementia Differentiate between dementia,
More informationUnderstanding Dementia
Understanding Dementia Dr. Dallas Seitz MD FRCPC Assistant Professor, Department of Psychiatry, Queen s University, Kingston, Ontario, Canada What s Next Information about Dementia, Elder Care and Supports
More informationBHIVA Best Practice Management Session
BHIVA Best Practice Management Session CNS (The brain) - I keep forgetting things DEMENTIA DIAGNOSIS, CLASSIFICATION AND INVESTIGATIONS Paul Holmes Consultant Neurologist Guy s and St Thomas Hospitals
More informationI do not have any disclosures
Alzheimer s Disease: Update on Research, Treatment & Care Clinicopathological Classifications of FTD and Related Disorders Keith A. Josephs, MST, MD, MS Associate Professor & Consultant of Neurology Mayo
More informationWhat About Dementia? Module 8, Part B (With Dr Allison Lamont)
What About Dementia? Module 8, Part B (With Dr Allison Lamont) Slide 1 Module 8 Part B will address the question What about dementia? Several surveys of older people both in the UK and USA have shown that
More informationCommon Forms of Dementia Handout Package
Common Forms of Dementia Handout Package Common Forms of Dementia 1 Learning Objectives As a result of working through this module, you should be better able to: 1. Describe clinical features of 4 major
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationASSESSMENT MILD COGNITIVE IMPAIRMENT. (i) Is the forgetfulness or confusion acute or chronic?
The main pathological hallmarks of AD are the Betaamyloid plaques and neurofibrillary tangles. The risk factors for the development of this pathology include advanced age, family history, vascular risk
More informationDementia Facts and Resources Dementia Warning Signs Getting a Diagnosis Dementia Communication Tips Dementia Risk Reduction.
Dementia Facts and Resources Dementia Warning Signs Getting a Diagnosis Dementia Communication Tips Dementia Risk Reduction Intermission Dementia Stages and Behaviors Caregiving and Self-Care Overview
More informationA Neurologist s Approach to Altered Mental Status
A Neurologist s Approach to Altered Mental Status S. Andrew Josephson, MD Department of Neurology University of California San Francisco October 23, 2008 The speaker has no disclosures Case 1 A 71 year-old
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More information3/6/2019 DIAGNOSIS OF DEMENTIA IN THE OUTPATIENT SETTING FINANCIAL DISCLOSURES LEARNING OBJECTIVES
DIAGNOSIS OF DEMENTIA IN THE OUTPATIENT SETTING MILTA LITTLE, DO, CMD DUKE UNIVERSITY SCHOOL OF MEDICINE FINANCIAL DISCLOSURES Dr. Little has no relevant financial disclosures to report Dr. Little will
More informationCognitive Evaluation in Primary Care. Scott T. Larson, MD Clinical Assistant Professor University of Iowa
Cognitive Evaluation in Primary Care Scott T. Larson, MD Clinical Assistant Professor University of Iowa scott-larson@uiowa.edu Objectives Understand the subtypes of dementia, and the DSM-5 categorization
More informationMild cognitive impairment A view on grey areas of a grey area diagnosis
Mild cognitive impairment A view on grey areas of a grey area diagnosis Dr Sergi Costafreda Senior Lecturer Division of Psychiatry, UCL Islington Memory Service, C&I NHS FT s.costafreda@ucl.ac.uk London
More informationDementia. Amber Eker, MD. Assistant Professor Near East University Department of Neurology
Dementia Amber Eker, MD Assistant Professor Near East University Department of Neurology Dementia An acquired syndrome consisting of a decline in memory and other cognitive functions Impairment in social
More informationThe Basics of Alzheimer s Disease
2017 Memory Loss Conference The Basics of Alzheimer s Disease Tom Ala, MD Center for Alzheimer s Disease and Related Disorders Southern Illinois University School of Medicine Springfield, Illinois SIU
More informationErin Cullnan Research Assistant, University of Illinois at Chicago
Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,
More informationNeuroimaging for dementia diagnosis. Guidance from the London Dementia Clinical Network
Neuroimaging for dementia diagnosis Guidance from the London Dementia Clinical Network Authors Dr Stephen Orleans-Foli Consultant Psychiatrist, West London Mental Health NHS Trust Dr Jeremy Isaacs Consultant
More informationAlzheimer s Disease. Fact Sheet. Fact Sheet. Fact Sheet. What Causes AD?
2 Alzheimer s Disease Dementia is a brain disorder that seriously affects a person s ability to carry out daily activities. The most common form of dementia among older people is Alzheimer s disease (AD),
More informationScope. EEG patterns in Encephalopathy. Diffuse encephalopathy. EEG in adult patients with. EEG in diffuse encephalopathy
Scope EEG patterns in Encephalopathy Dr.Pasiri Sithinamsuwan Division of Neurology Department of Medicine Phramongkutklao Hospital Diffuse encephalopathy EEG in specific encephalopathies Encephalitides
More informationNACC Minimum Data Set (MDS) Public Data Element Dictionary
Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu
More informationUDS version 3 Summary of major changes to UDS form packets
UDS version 3 Summary of major changes to UDS form packets from version 2 to VERSION 3 february 18 final Form A1: Subject demographics Updated question on principal referral source to add additional options
More informationIntroduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge
Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes
More informationDementia: It s Not Always Alzheimer s
Dementia: It s Not Always Alzheimer s A Caregiver s Perspective Diane E. Vance, Ph.D. Mid-America Institute on Aging and Wellness 2017 My Background Caregiver for my husband who had Lewy Body Dementia
More informationDelirium, Dementia, and Amnestic Disorders. Dr.Al-Azzam 1
Delirium, Dementia, and Amnestic Disorders Dr.Al-Azzam 1 Introduction Disorders in which a clinically significant deficit in cognition or memory exists The number of people with these disorders is growing
More informationWestminster Memory Services Pathways Toolkit (updated October 2016)
Westminster Memory Services Pathways Toolkit (updated October 2016) Contents Aims... 2 Memory loss experienced by service users... 2 Signs of memory loss... 2 Alcohol dependency and memory loss... 3 Other
More informationDEMENTIA. Stephanie Janka Spurlock and Mandy Nagy T&SDFT trainers and assessors
DEMENTIA Stephanie Janka Spurlock and Mandy Nagy T&SDFT trainers and assessors amanda.nagy@nhs.net Definition Dementia is an umbrella term used to describe a set of symptoms that may include memory loss
More information